- Home
- SBCF vs CELC Comparison
SBCF vs CELC Comparison
Compare SBCF & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SBCF | CELC |
|---|---|---|
| Founded | 1926 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.1B |
| IPO Year | 2009 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SBCF | CELC |
|---|---|---|
| Price | $29.25 | $113.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $32.00 | ★ $106.63 |
| AVG Volume (30 Days) | ★ 683.0K | 533.5K |
| Earning Date | 04-23-2026 | 03-25-2026 |
| Dividend Yield | ★ 2.60% | N/A |
| EPS Growth | ★ 10.56 | N/A |
| EPS | ★ 1.57 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $45.75 | N/A |
| Revenue Next Year | $6.17 | N/A |
| P/E Ratio | $18.58 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.48 | $7.58 |
| 52 Week High | $35.55 | $120.32 |
Technical Indicators
Market Signals| Indicator | SBCF | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 32.18 | 53.90 |
| Support Level | $27.78 | $97.75 |
| Resistance Level | $29.99 | $117.27 |
| Average True Range (ATR) | 0.96 | 5.10 |
| MACD | -0.17 | 0.07 |
| Stochastic Oscillator | 0.15 | 58.79 |
Price Performance
Historical ComparisonAbout SBCF Seacoast Banking Corporation of Florida
Seacoast Banking Corp of Florida is a holding company for Seacoast National Bank. The company provides integrated financial services including commercial and consumer banking, wealth management, and mortgage and insurance services to customers across Florida, and through mobile and online banking solutions. In addition, it provides services such as treasury management, brokerage and credit facilities.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.